Home » Stocks » RLAY

Relay Therapeutics, Inc. (RLAY)

Stock Price: $32.26 USD -0.37 (-1.13%)
Updated Apr 20, 2021 4:00 PM EDT - Market closed
Market Cap 2.94B
Revenue (ttm) 82.65M
Net Income (ttm) -230.20M
Shares Out 90.43M
EPS (ttm) -5.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 20
Last Price $32.26
Previous Close $32.63
Change ($) -0.37
Change (%) -1.13%
Day's Open 32.29
Day's Range 31.50 - 32.99
Day's Volume 214,572
52-Week Range 30.72 - 64.37

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Advanced two programs, RLY-1971 and RLY-4008, into clinical development, and on track to initiate IND enabling studies with PI3Kα mutant selective inhibitor in 2021

3 weeks ago - GlobeNewsWire

RLY-4008 demonstrates strong activity against known clinical on-target resistance mutations in cellular and in vivo preclinical models RLY-4008 demonstrates strong activity against known clinical on-tar...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day on Thursda...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 4...

3 months ago - GlobeNewsWire

Collaboration brings together clinical stage SHP2 and KRAS G12C inhibitors

4 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparallele...

5 months ago - GlobeNewsWire

Relay Therapeutics: Heavily Backed Biotech Brains Trust Looks A Long-Term Buy

7 months ago - Seeking Alpha

CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparall...

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalle...

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalle...

9 months ago - GlobeNewsWire

TAIPEI, Taiwan--(BUSINESS WIRE)--Oak Stone Limited says SoftBank-backed Relay Therapeutics has soared 75% in its trading debut, expanding its IPO to raise $400 million.

9 months ago - Business Wire

IPOS to watch: Relay Therapeutics and Trean Insurance Group

YouTube video

Yahoo Finance's Jared Blikre breaks down IPOs Relay Therapeutics and Trean Insurance Group.

9 months ago - Yahoo Finance

Shares of Relay Therapeutics Inc. RLAY, +67.10% sprinted out of the gate Thursday, after the clinical-stage oncology company's upsized initial public offering priced above the expected range.

9 months ago - Market Watch

Relay Therapeutics raised $400 million with an initial public offering that priced late Wednesday and surpassed expectations. The Relay Therapeutics IPO will begin trading Thursday morning.

9 months ago - Investors Business Daily

About RLAY

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company's lead product candidates include RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth facto... [Read more...]

Industry
Biotechnology
IPO Date
Jul 16, 2020
Stock Exchange
NASDAQ
Ticker Symbol
RLAY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for RLAY stock is "Buy." The 12-month stock price forecast is 54.40, which is an increase of 68.63% from the latest price.

Price Target
$54.40
(68.63% upside)
Analyst Consensus: Buy